IGM Biosciences Inc (IGMS) is a clinical-stage biotechnology company that focuses on the development of engineered IgM antibodies for the treatment of cancer and other diseases. The company's lead product candidate, IGM-2323, is a bispecific antibody designed to target CD20 and CD3 proteins, which are overexpressed in B-cell malignancies. IGM-2323 is currently in Phase 1 clinical trials for the treatment of non-Hodgkin lymphoma and other B-cell malignancies. IGM Biosciences is also developing other product candidates, including IGM-8444, which targets death receptor 5 (DR5) for the treatment of solid tumors, and IGM-7354, which targets CTLA-4 and LAG-3 for the treatment of advanced solid tumors. The company is headquartered in Mountain View, California, and as of September 2021, had a market capitalization of approximately $1.9 billion.
IGM Biosciences Inc (IGMS) is a clinical-stage biotechnology company that focuses on the development of engineered IgM antibodies for the treatment of cancer and other diseases. The company's lead product candidate, IGM-2323, is a bispecific antibody designed to target CD20 and CD3 proteins, which are overexpressed in B-cell malignancies. IGM-2323 is currently in Phase 1 clinical trials for the treatment of non-Hodgkin lymphoma and other B-cell malignancies. IGM Biosciences is also developing other product candidates, including IGM-8444, which targets death receptor 5 (DR5) for the treatment of solid tumors, and IGM-7354, which targets CTLA-4 and LAG-3 for the treatment of advanced solid tumors. The company is headquartered in Mountain View, California, and as of September 2021, had a market capitalization of approximately $1.9 billion.